Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies

New Directions

Daniel S. Jamorabo, Steven H. Lin, Salma Jabbour

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Upper gastrointestinal malignancies generally have moderate to poor cure rates, even in the earliest stages, thereby implying that both local and systemic treatments have room for improvement. Therapeutic options are broadening, however, with the development of new immunotherapies and targeted agents, which can have synergistic effects with radiotherapy. Here we discuss the current state of combined modality therapy for upper gastrointestinal malignancies, specifically recent successes and setbacks in trials of radiation therapy with targeted therapies, vaccines, immunotherapies, and chemotherapies.

Original languageEnglish (US)
Pages (from-to)307-319
Number of pages13
JournalSeminars in Radiation Oncology
Volume26
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Immunotherapy
Radiotherapy
Active Immunotherapy
Combined Modality Therapy
Neoplasms
Drug Therapy
Therapeutics
Direction compound

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{ef13ef6a53f14d9ab2bab019634e442e,
title = "Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions",
abstract = "Upper gastrointestinal malignancies generally have moderate to poor cure rates, even in the earliest stages, thereby implying that both local and systemic treatments have room for improvement. Therapeutic options are broadening, however, with the development of new immunotherapies and targeted agents, which can have synergistic effects with radiotherapy. Here we discuss the current state of combined modality therapy for upper gastrointestinal malignancies, specifically recent successes and setbacks in trials of radiation therapy with targeted therapies, vaccines, immunotherapies, and chemotherapies.",
author = "Jamorabo, {Daniel S.} and Lin, {Steven H.} and Salma Jabbour",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.semradonc.2016.05.001",
language = "English (US)",
volume = "26",
pages = "307--319",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies : New Directions. / Jamorabo, Daniel S.; Lin, Steven H.; Jabbour, Salma.

In: Seminars in Radiation Oncology, Vol. 26, No. 4, 01.10.2016, p. 307-319.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies

T2 - New Directions

AU - Jamorabo, Daniel S.

AU - Lin, Steven H.

AU - Jabbour, Salma

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Upper gastrointestinal malignancies generally have moderate to poor cure rates, even in the earliest stages, thereby implying that both local and systemic treatments have room for improvement. Therapeutic options are broadening, however, with the development of new immunotherapies and targeted agents, which can have synergistic effects with radiotherapy. Here we discuss the current state of combined modality therapy for upper gastrointestinal malignancies, specifically recent successes and setbacks in trials of radiation therapy with targeted therapies, vaccines, immunotherapies, and chemotherapies.

AB - Upper gastrointestinal malignancies generally have moderate to poor cure rates, even in the earliest stages, thereby implying that both local and systemic treatments have room for improvement. Therapeutic options are broadening, however, with the development of new immunotherapies and targeted agents, which can have synergistic effects with radiotherapy. Here we discuss the current state of combined modality therapy for upper gastrointestinal malignancies, specifically recent successes and setbacks in trials of radiation therapy with targeted therapies, vaccines, immunotherapies, and chemotherapies.

UR - http://www.scopus.com/inward/record.url?scp=84995394485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995394485&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2016.05.001

DO - 10.1016/j.semradonc.2016.05.001

M3 - Review article

VL - 26

SP - 307

EP - 319

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 4

ER -